Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...
BioPharma Dive

Regeneron inks gene editing deal with startup Tessera

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...
AOL

Does the 23andMe Acquisition Make Regeneron a Buy Now?

Have you ever wondered if an established drugmaker could do better at genetics-guided research than a consumer-focused diagnostics business? Well, we could find out. Where to invest $1,000 right now?
U.S. News & World Report

Regeneron Declines to Make Higher Bid for 23andMe After Wojcicki's $305 Million Offer

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday. WHY ...

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...